Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Precirix N.V.

Precirix is a private, clinical-stage biopharmaceutical company founded in 2014 as a spin-off from the VUB, dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labelled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’s technology also allows for a theragnostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a therapeutic dose for treatment. *

 

Period Start 2020-09-21 renamed
  Predecessor Camel-IDS (BE)
Product Industry RADIOPHARMACEUTICAL (RPT)
Person Person Devenyns, Ruth (Precirix 202009 CEO formerly KBC 200910 KBC Private Equity)
     
Region Region Brussels
  Country Belgium
  Street 1 Burgemeester Etienne Demunterlaan
  City 1090 Brussels
  Tel +32-2-479-9360
    Address record changed: 2022-03-22
     
Basic data Employees n. a.
     
    * Document for »About Section«: Precirix N.V.. (3/16/22). "Press Release: Precirix Raises EUR 80m in Series B to Advance Its Pipeline of Precision Radiopharmaceuticals". Brussels.
     
   
Record changed: 2024-03-11

Advertisement

Picture Berlin Partner Top News Captain T Cell Therapies 650x200px

More documents for Precirix N.V.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px




» top